Sarah Adly: Our Article on ‘Optimizing Outcomes in Advanced Renal Cell Carcinoma’

Sarah Adly, NCODA Fellow in Oncology, made the following post on LinkedIn:      .

“I am thrilled to announce the publication of our article, ‘Optimizing Outcomes in Advanced Renal Cell Carcinoma,’ in the June edition of Men’s Health by U. S. Pharmacist under Specialty and Oncology Health Systems Edition (pages HS-2-3, HS-9-10). Guided by Tina Caliendo, PharmD, BCGP, BCACP expertise, we collaborated on a topic that is close to my heart. Advanced Renal Cell Carcinoma (RCC), a metastatic kidney cancer primarily affecting men, poses a significant oncological challenge due to its increasing incidence and complex pathophysiology.

This article referenced the KEYNOTE-426 clinical trial and compared primary and secondary endpoints in monotherapy vs combination therapy. Recent treatment advancements, particularly the combination of immune checkpoint inhibitors with VEGFR tyrosine kinase inhibitors, show promise in improving overall survival and progression-free survival rates.

Despite obstacles such as high treatment costs and medication shortages, pharmacists play a crucial role in optimizing cancer care outcomes. Through collaboration with healthcare teams and patient advocacy, pharmacists aim to enhance the quality of life for individuals battling advanced RCC, ensuring comprehensive support throughout their treatment journey.

As referenced on page HS-10, I dedicated this article to my father, who recently passed away following a decade-long battle with metastatic RCC. As healthcare professionals, it is crucial that we receive proper training on available therapeutic options and effectively combine these with supportive care techniques to enhance patient outcomes.

I would like to extend my deepest appreciation to Tina Caliendo, PharmD, BCGP, BCACP for her invaluable guidance and steadfast support throughout this journey. Her mentorship has been instrumental in the success of our article.”

Source: Sarah Adly/LinkedIn